arGEN-X N.V. | Balance Sheet

Fiscal year is January-December. All values EUR Thousands.
2013
2014
2015
2016
2017
2018
Cash & Short Term Investments
23,220.00
55,973.00
42,327.00
97,514.00
361,466.00
566,261
Total Accounts Receivable
1,101.00
1,312.00
1,356.00
2,133.00
3,000.00
3,187
Other Current Assets
106.00
92.00
454.00
2,146.00
2,338.00
2,995
Total Current Assets
24,427.00
57,377.00
44,137.00
101,793.00
366,804.00
572,443
Net Property, Plant & Equipment
120.00
166.00
249.00
766.00
676.00
824
Total Investments and Advances
1.00
1.00
1.00
1,150.00
257.00
252
Long-Term Note Receivable
465.00
959.00
1,568.00
2,046.00
3,133.00
4,883
Intangible Assets
-
7.00
7.00
17.00
13.00
56
Other Assets
-
-
-
-
25.00
-
Total Assets
25,013.00
58,510.00
45,962.00
105,772.00
370,908.00
578,458
Accounts Payable
2,097.00
3,375.00
2,711.00
4,385.00
4,395.00
Income Tax Payable
-
-
-
-
597.00
Other Current Liabilities
1,212.00
5,053.00
5,973.00
38,012.00
20,960.00
Total Current Liabilities
3,309.00
8,428.00
8,684.00
42,397.00
25,952.00
Provision for Risks & Charges
-
-
-
1.00
25.00
Total Liabilities
3,309.00
8,428.00
8,684.00
42,398.00
25,977.00
Common Equity (Total)
21,256.00
50,082.00
37,278.00
63,374.00
344,931.00
Total Shareholders' Equity
21,704.00
50,082.00
37,278.00
63,374.00
344,931.00
Total Equity
21,704.00
50,082.00
37,278.00
63,374.00
344,931.00
Liabilities & Shareholders' Equity
25,013.00
58,510.00
45,962.00
105,772.00
370,908.00
Preferred Stock (Carrying Value)
448.00
-
-
-
-

About arGEN-X

View Profile
Address
Willemstraat 5
Breda Noord-Brabant 4811 AH
Netherlands
Employees -
Website http://www.argen-x.com
Updated 07/08/2019
argenx SE is a clinical-stage biotechnology company, which engages in the research and development of human monoclonal antibodies for the treatment of cancer and oncological, autoimmune, and inflammatory diseases. Its products include ARGX-113 for severe autoimmune diseases and ARGX-110 for T-cell lymphoma and acute myeloid leukemia. It operates through the following geographical segments: Netherlands, Belgium, Germany, Denmark, Switzerland, United States, and Luxemburg.